Home › Brain Tumors › NCT06099743
Supportive Psychoeducational Intervention for Patients With Brain Tumors (Acceptance and Commitment Therapy-based Supportive Intervention for Patients With Central Nervous System Tumors)
An ACT-Based Supportive Intervention for Patients With Central Nervous System Tumors
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥ 18 * Massachusetts General Hospital Cancer Center Patient * Diagnosed with a malignant primary Central Nervous System (CNS) tumor * English speaking Exclusion Criteria: * Inability to provide informed consent as assessed by the study team (e.g., due to severe cognitive impairment/dementia) * Moderate to severe receptive aphasia (Quick Aphasia Battery sentence comprehension subscale \< 8) * Deemed by treating team to have less than 6 month life expectancy, including patients with current or imminent hospice enrollment * Current participant in the NeuroTransitions (23-574) or NeuroPathways (23-178) studies at Massachusetts General Hospital * Diagnosis of Primary CNS Lymphoma
About the study
The goal of this study is to refine and test a psychosocial intervention called ASCENT (ACT-based Supportive intervention for patients with CENTral nervous system tumors). This intervention was developed to help patients after being diagnosed with a brain tumor. The main question this study aims to answer is whether this intervention is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in 6 coaching sessions and complete short surveys at four different time points. Some participants will be asked to share feedback via interviews.
What is being tested
- Psychosocial intervention (behavioral)
- Usual supportive care (other)
Sponsor: Massachusetts General Hospital · Participants: 100 · Started: May 15, 2025
Contact the study team
- Deborah A Forst, MD · Phone: 617-724-4000
Official record on ClinicalTrials.gov — NCT06099743
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital Cancer Center, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.